Incidental findings of monoclonal proteins from carbohydrate-deficient transferrin analysis using capillary electrophoresis

Kjersti Oppen 1 , Johan Bjerner 1 , Marie Buchmann 1  and Armin P. Piehler 2
  • 1 Fürst Medical Laboratory, Oslo, Norway
  • 2 Fürst Medical Laboratory, Søren Bullsvei 25, 1051 Oslo, Norway
Kjersti Oppen, Johan Bjerner, Marie Buchmann and Armin P. Piehler

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1.

    Stibler H. Carbohydrate-deficient transferrin in serum: a new marker of potentially harmful alcohol consumption reviewed. Clin Chem 1991;37:2029–37.

  • 2.

    Bird J, Behrens J, Westin J, Turesson I, Drayson M, Beetham R, et al. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol 2009;147:22–42.

  • 3.

    Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006;354:1362–9.

  • 4.

    Burtis CA, Ashwood ER, Bruns DE, Tietz NW, editors. Tietz textbook of clinical chemistry and molecular diagnostics. 5th ed. St. Louis, Mo: Saunders; 2013:553.

  • 5.

    Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos M-V, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15:e538–48.

  • 6.

    Cole C, Petree LE, Phillips JP, Shoemaker JM, Holdsworth M, Helitzer DL, et al. “Ethical responsibility” or “a whole can of worms”: differences in opinion on incidental finding review and disclosure in neuroimaging research from focus group discussions with participants, parents, IRB members, investigators, physicians and community members. J Med Ethics 2015;41:841–7.

  • 7.

    Green RC, Berg JS, Grody WW, Kalia SS, Korf BR, Martin CL, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med Off J Am Coll Med Genet 2013;15:565–74.

  • 8.

    Rajkumar SV, Kyle RA, Therneau TM, Melton LJ, Bradwell AR, Clark RJ, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005;106:812–7.

  • 9.

    Sigurdardottir EE, Turesson I, Lund SH, Lindqvist EK, Mailankody S, Korde N, et al. The role of diagnosis and clinical follow-up of monoclonal gammopathy of undetermined significance on survival in multiple myeloma. J Am Med Assoc Oncol 2015;1:168–17.

  • 10.

    Go RS, Gundrum JD, Neuner JM. Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-medicare population analysis. Clin Lymphoma Myeloma Leuk 2015;15:177–86.e4.

Purchase article
Get instant unlimited access to the article.
$42.00
Log in
Already have access? Please log in.


Journal + Issues

Clinical Chemistry and Laboratory Medicine ( CCLM) publishes articles on novel teaching and training methods applicable to laboratory medicine. CCLM welcomes contributions on the progress in fundamental and applied research and cutting-edge clinical laboratory medicine. It is one of the leading journals in the field, with an impact factor of over three. CCLM is the official journal of nine national clinical societies and associated with EFLM.

Search